Cited by 1,012Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Open access

Attia, Peter, Phan, Giao Q., Maker, Ajay V., Robinson, Michael R., Quezado, Martha M., Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Restifo, Nicholas P., Haworth, Leah R., Levy, Catherine, Mavroukakis, Sharon A., Nichol, Geoff, Yellin, Michael J., Rosenberg, Steven A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.06.205PMC PMC1473965

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) in conjunction with peptide vaccination. We have now treated 56 patients to evaluate two different dose schedules of anti–CTLA-4 and to explore the relationship between autoimmunity and tumor regression. Patients and Methods: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study. All had Karnofsky performance status ≥ 60% with no prior history of autoimmunity. Twenty-nine patients received 3 mg/kg anti–CTLA-4 every 3 weeks, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg every 3 weeks. In both cohorts patients received concomitant vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). Results: Two patients achieved a complete response (ongoing at 30 and 31 months, respectively) and five patients achieved a partial response (durations of 4, 6, 25+, 26+, and 34+ months, respectively), for an overall objective response rate of 13%. Tumor regression was seen in lung, liver, brain, lymph nodes, and subcutaneous sites. Of 14 patients with grade 3/4 autoimmune toxicity, five (36%) experienced a clinical response compared with only two responses in the 42 patients (5%) with no autoimmune toxicity (P = .008). There were no significant differences in response rate or toxicity between the two dose schedules. Conclusion: Administration of anti–CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.06.205

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,860
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri821 · Cited by 2,097

Flagged first, then by citations

Show all 44 references

Sorted by citations

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citation
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Self-citation
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,498
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C.-H., Morgan, R. A., & Dudley, M. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2355 · Cited by 1,654
Self-citation
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Royal, R. E., Levy, C. L., Turner, K. M., Mathur, A., Hughes, M. S., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C.-H., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,266
Self-citation
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,013
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J. S., Gailani, F., Riley, L. B., Conlon, K. C., Pockaj, B. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 935
Self-citation
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J., Tran, D. Q., Stoddard, J. L., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 879
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Self-citation
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 843
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
Self-citation
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 706
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 646
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 640
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Self-citation
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 633
Self-citation
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
Reck, M., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Lü, H., Cuillerot, J.-M., & Lynch, T. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 613
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Garbe, C., Eigentler, T., Keilholz, U., Hauschild, A., & Kirkwood, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0190 · Cited by 591
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 583
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 583
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Weber, J. S., Thompson, J. A., Hamid, O., Minor, D. R., Amin, A., Ron, I. G., Ridolfi, R., Assi, H. I., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 566
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Puzanov, I. J., Milhem, M. M., Minor, D. R., Hamid, O., Ai, L., Chen, L., Chastain, M. A., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 576
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A. L., Alumkal, J. J., Scher, H. I., Chin, K. M., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 560
Cutaneous melanoma
Eggermont, A. M. M., Spatz, A., & Robert, C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60802-8 · Cited by 585
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
“Early clinical studies reported a correlation between the occurrence of autoimmunity after ipilimumab and favorable clinical outcome (7, 8).”
Background
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
Zhong, X.-S., Matsushita, M., Plotkin, J., Rivière, I., & Sadelain, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 564
VISTA is an immune checkpoint molecule for human T cells
Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S., Suriawinata, A. A., Yan, S., Ernstoff, M. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1504 · Cited by 510
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
O'Day, S., Maio, M., Chiarion-Sileni, V., Gajewski, T., Pehamberger, H., Bondarenko, I., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 506
Advances in targeted therapy for esophageal cancer
Yang, Y., Hong, P., Xu, W. W., He, Q., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 511
Malignant melanoma: genetics and therapeutics in the genomic eraPreprint
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 524
When worlds collide: Th17 and Treg cells in cancer and autoimmunity
Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Giles, A. J., Hutchinson, M.-K. N. D., Sonnemann, H. M., Jung, J., Fecci, P. E., Ratnam, N. M., Zhang, W., Song, H., Bailey, R., Davis, D. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0371-5 · Cited by 507
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
Self-citation
Immune Regulation of Cancer
Disis, M. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2146 · Cited by 504
Immune checkpoint inhibitor–related dermatologic adverse events
Geisler, A. N., Phillips, G. S., M.S, D. M. B., Wu, J., Leung, D. Y. M., Moy, A. P., Kern, J. A., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.132 · Cited by 502
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 485
Self-citation
Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation
Ízcue, A., Coombes, J. L., & Powrie, F. M. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00423.x · Cited by 481
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
Self-citation
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 448
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01406-6 · Cited by 437
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
Eggermont, A. M. M., Kiciński, M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Khattak, A., Carlino, M. S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5570 · Cited by 440
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
Ku, G. Y., Yuan, J. D., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 418
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Drake, C. G., Lipson, E. J., & Brahmer, J. R. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.208 · Cited by 430
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
Belum, V. R., Benhuri, B., Postow, M. A., Hellmann, M. D., Lesokhin, A. M., Segal, N. H., Motzer, R. J., Wu, S., Busam, K. J., Wolchok, J. D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.010 · Cited by 418
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709802104 · Cited by 401
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 405
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0081-1 · Cited by 394
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
Hussaini, S. M. Q., Chehade, R., Boldt, G., Raphael, J., Blanchette, P., Vareki, S. M., & Fernandes, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102134 · Cited by 412
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., Mok, S., Huang, R., Cochran, A. J., Comı́n-Anduix, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2648 · Cited by 383
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S., Morris, L., Holland, H., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 343
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael, Y., Johnson, D. H., Abdel‐Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 372
Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer
Blansfield, J., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C. L., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 354
Self-citation
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
Cho, J., Kim, H. S., Ku, B. M., Choi, Y., Cristescu, R., Han, J., Sun, J., Lee, S., Ahn, J. S., Park, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.3184 · Cited by 349
Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 342
Self-citation
Immunodeficiency and immunotherapy in multiple myeloma
Pratt, G., Goodyear, O. C., & Moss, P. A. H. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06705.x · Cited by 342
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 340
Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
Fong, L. H., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 320
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, É., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41068 · Cited by 317
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Andtbacka, R. H. I., Ross, M., Puzanov, I. J., Milhem, M. M., Collichio, F. A., Delman, K. A., AMATRUDA, T. T., Zager, J. S., Cranmer, L. D., Hsueh, E. C., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5286-0 · Cited by 308
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
Hersh, E. M., O'Day, S. J., Powderly, J. D., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Samlowski, W. E., Nichol, G. M., Yellin, M. J., & Weber, J. S. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9376-8 · Cited by 305
Self-citation
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Wolchok, J. D., Hodi, F. S., Weber, J. S., Allison, J. P., Urba, W. J., Robert, C., O'Day, S. J., Hoos, A., Humphrey, R. W., Berman, D. M., et al. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12180 · Cited by 309
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 301
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., Kapiteijn, E., de Groot, J. W. B., Soetekouw, P. M. M. B., Jansen, R. L. H., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1528-9 · Cited by 307
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Dillard, T. H., Yedinak, C. G., Alumkal, J. J., & Fleseriu, M. (2009) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 296
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Giacomo, A. M. D., Danielli, R., Guidoboni, M., Calabrò, L., Carlucci, D., Miracco, C., Volterrani, L., Mazzei, M. A., BIAGIOLI, M., Altomonte, M., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0642-y · Cited by 287
Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events
Weber, J. S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-864 · Cited by 284
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Albarel, F., Gaudy‐Marqueste, C., Castinetti, F., Carré, T., Morange, I., Conte‐Devolx, B., Grob, J., & Brue, T. C. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0845 · Cited by 287
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 284
Systematic review: colitis associated with anti‐ CTLA ‐4 therapy
Gupta, A., Felice, K. M. D., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 277
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M. S., Yellin, M. J., Haworth, L. R., Levy, C. L., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 264
Self-citation
Principles of adoptive T cell cancer therapy
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31446 · Cited by 261
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez‐Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 254
Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity
Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Wolchok, J. D., & Saenger, Y. M. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-2 · Cited by 255

Authors: Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Restifo, N. P., Haworth, L. R., Levy, C., Mavroukakis, S. A., Nichol, G., Yellin, M. J., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
ORCID: Phan, Giao Q.
Maker, Ajay V.
Robinson, Michael R.
Quezado, Martha M.
Yang, James C.
Sherry, Richard M.
Topalian, Suzanne L.
Kammula, Udai S.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Yellin, Michael J.
Rosenberg, Steven A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 6043-6053
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.06.205
PMC: PMC1473965
OpenAlex: W2151507811
Cited by: 1,012
References: 44
Citations by year: 2026: 6 · 2025: 15 · 2024: 18 · 2023: 17 · 2022: 31 · 2021: 45 · 2020: 81 · 2019: 46 · 2018: 45 · 2017: 55 · 2016: 60 · 2015: 64 · 2014: 49 · 2013: 63 · 2012: 43
FWCI: 30.93
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: metastatic melanoma, anti-CTLA-4 monoclonal antibody, CTLA-4 blockade, autoimmunity, autoimmune toxicity, tumor regression, peptide vaccination, gp100, dosing regimen, immune checkpoint inhibitors, objective response rate
MeSH terms: Adult, Aged, Antigens, Differentiation, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents, Injections, Intravenous, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Autoimmunity, Antigens, CD, Treatment Outcome, Cancer Vaccines, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks